中基長壽科學(00767.HK)與癌症篩查相關重要專利獲香港特別行政區政府知識產權署專利註冊處審批註冊
格隆匯5月11日丨中基長壽科學(00767.HK)公吿,旗下亞洲先進醫療檢測中心擁有癌症篩查和監察的先進和非侵入性的檢測技術相關的重要專利已於香港特別行政區政府知識產權署專利註冊處審批註冊。
與該專利相關的技術有效直接於外周血中分離循環腫瘤細胞,用於液體活檢,簡化富集循環腫瘤細胞的分離工序,提高循環腫瘤細胞的回收效率,解決了現有技術流失大量循環腫瘤細胞的技術瓶頸。
與該專利相關的技術可將循環腫瘤細胞進行多重免疫熒光染色,和利用光學生物成像方法,有效偵測和準確分辨多種的循環腫瘤細胞,提高循環腫瘤細胞偵測的敏感度和特異性,尤其在循環腫瘤細胞數量較低的時候,表現更為突出。
該專利相關的技術,顯著提昇了癌症早篩的有效性和準確性,增強了公司長壽醫學檢測的領先地位,有助於人類有效預防和治療癌症。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.